Fotofantastika Dear readers/followers, I've been very careful about pharma company Bayer (OTCPK:BAYRY) since my last article. You can find that particular article here. When I last wrote about Bayer, the company had just cut the dividend to the bone (less than 1% at the time of publishing of that piece). It's fair to say that the fortunes for Bayer have turned around over the past 3 years and that there's according to the valuation not much reason for near-term optimism to be had here. The cases to be made ...